摘要:
A system is disclosed for reducing power drain of a component when the component is in a powered down state. The system comprises a power input configured to receive power, a power output to the component, monitor logic configured to monitor a level of power moving between the input and output, and control logic configured to control power transfer between the input and output. The control logic may be in communication with the monitor logic and configured to selectively restrict power flow between the input and output when the monitor logic senses that power flow between the input and output falls below a threshold level. A method comprises checking a power level between the input and output, and if the power level exceeds a threshold, then permitting substantially unrestricted power flow. If the power level is less than the threshold, then restricting the power level between the input and output.
摘要:
This invention concerns the use of a compound of formula (I′) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; aminocarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C1-4alkyl substituted piperidinyl, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC1-4alkyl; cyano; amino; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; aminoS(═O)2—; mono- or di(C1-6alkyl)aminoS(═O)2; —C(═N—Rx)NRyRz; Q is optionally substituted C3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12.
摘要翻译:本发明涉及式(I')化合物的N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构体形式的用途,其中Z为卤素; C 1-6烷基; C 1-6烷基羰基; C 1-6烷氧基羰基; 氨基羰基; 被羟基,羧基,氰基,氨基,被哌啶取代的氨基,被C 1-4烷基取代的哌啶基取代的氨基,单或二(C 1-6烷基)氨基,氨基羰基,一或二(C 1-6烷基)氨基羰基 C 1-6烷氧基羰基,C 1-6烷氧基,哌啶基,哌嗪基,吗啉基,硫代吗啉基; 多卤代C 1-4烷基; 氰基; 氨基; 单或二(C 1-6烷基)氨基羰基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 氨基S(= O)2-; 单或二(C 1-6烷基)氨基S(= O)2; -C(= N-Rx)NR y R z; Q是任选取代的C 3-6环烷基,苯基,吡啶基,嘧啶基,吡嗪基,哒嗪基,苯并噻唑基,苯并恶唑基,苯并咪唑基,吲唑基或咪唑并吡啶基,或Q是式L的基团是任选取代的苯基或任选取代的单环5或6- 元部分饱和或芳族杂环或双环部分饱和或芳族杂环; 芳基是任选取代的苯基; 用于制备用于预防或治疗通过TNF-α和/或IL-12介导的炎症和/或自身免疫疾病的药物。
摘要:
A multiaxial hinge assembly that enables rotation about a first axis between a clockwise limit and a counterclockwise limit and also enables rotation about a second axis that is orthogonal to the first includes a rotational direction indicator to provide an indication of a direction of rotation about the first axis to reduce the likelihood of rotation against the clockwise or counterclockwise limits and possible damage to the hinge assembly, or connected apparatus, or both. In one example, the multiaxial hinge assembly may be used for mounting the display of a hybrid notebook/tablet PC to provide an indication to a user of the direction in which the display may be counter-rotated when the hinge is positioned at either the clockwise or counterclockwise limits.
摘要:
This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 is C1-6alkyloxy, C2-6alkenyloxy or C2-26alkynyloxy; R2 is hydrogen or C1-6alkyloxy, or when taken together R1 and R2 may form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl, R3 is hydrogen or halo; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl optionally substituted with aryl, or L is a radical of formula —Alk—R4, —Alk—NR5R6, 1-R6-4-piperidinyl, Alk—X—R7, —Alk—Y—C(═O)—R9, or —Alk—Y—C(═O)—NR11R12 wherein each Alk is C1-12alkanediyl; R4 is hydrogen, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, Ar—, di(Ar)methyl, Ar-oxy- or Het1; R5 is hydrogen or C1-6alkyl; R6 is Het2; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, Ar or Het2; X is O, S, SO2 or NR8; said R8 being hydrogen, C1-6alkyl or Ar; R9 is hydrogen, C1-6alkyl, C3-6cyclo-alkyl, Ar, ArC1-6alkyl, di(Ar)methyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, C1-6alkyl or Ar; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, Ar or ArC1-6alkyl, or R11 and R12 combined with the nitrogen atom bearing R11 and R12 may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C1-6alkyl, amino or mono or di(C1-6alkyl)amino, or said R11 and R12 combined with the nitrogen bearing R11 and R12 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C1-6alkyl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
摘要翻译:本发明涉及配制N-氧化物形式的化合物,其药学上可接受的酸加成盐及其立体化学异构形式,其中R 1为C 1-6烷氧基,C 2-6烯氧基或C 2-6-26炔氧基; R 2是氢或C 1-6烷氧基,或者当R 1和R 2一起可以形成下式的二价基团时,其中在所述二价基团中,一个或两个氢原子可以被C 1-6烷基取代,R 3是氢或卤素; L是C3-6环烷基,C5-6环烷酮,任选被芳基取代的C 2-6链烯基,或L是式-Alk-R 4,-Alk-NR 5 R 6,1-R 6 其中每个Alk为C1(= O)-R9,-Alk-YC(= O)-NR11R12,其中每个Alk为C1 -12烷二基; R 4是氢,C 1-6烷基磺酰基氨基,C 3-6环烷基,C 5-6环烷酮,Ar-,二(Ar)甲基,Ar-氧基或Het 1。 R 5是氢或C 1-6烷基; R 6是Het 2; R 7是氢,C 1-6烷基,羟基C 1-6烷基,C 3-6环烷基,Ar或Het 2; X是O,S,SO 2或NR 8; 所述R 8为氢,C 1-6烷基或Ar; R 9是氢,C 1-6烷基,C 3-6环烷基,Ar,ArC 1-6烷基,二(Ar)甲基,C 1-6烷氧基或羟基; Y是NR 10或直接键; 所述R 10为氢,C 1-6烷基或Ar; R 11和R 12各自独立地为氢,C 1-6烷基,C 3-6环烷基,Ar或ArC 1-6烷基,或R 11和R 12与带有R 11和R 10的氮原子结合 可以形成任选被C
摘要:
A hydrometallurgical process for the recovery of nickel and cobalt values from a sulfidic flotation concentrate. The process involves forming a slurry of the sulfidic flotation concentrate in an acid solution, and subjecting the slurried flotation concentrate to a chlorine leach at atmospheric pressure followed by an oxidative pressure leach. After liquid-solids separation and purification of the concentrate resulting in the removal of copper and cobalt, the nickel-containing solution is directly treated by electrowinning to recover nickel cathode therefrom.
摘要:
Compounds of formula I the N-oxide forms, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the substituents are as described in the specification, and process for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
摘要:
The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I).
摘要:
This invention relates to a continuous vacuum pan (also sometimes referred to as an evaporative crystallizer) for use in the sugar processing industry, and to a heat exchanger used inside the continuous vacuum pan. The invention also relaters to the heat exchanger as used in other applications in the sugar processing industry. The heat exchanger includes a massecuite flow path for conveying massecuite therethrough, and a heat transfer medium flow path for receiving a heat transfer medium to enable heat transfer to the massecuite flow path. The heat exchanger is characterized therein that a periphery thereof is surrounded by an insulated zone in order to prevent heat transfer from the heat transfer medium flow path to the environment.
摘要:
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents 1, n represents 1, Z represents N or C, in particular N; —X1— represents C1-4alkyl, in particular methyl; —X2— represents —C1-4alkyl- or —C1-4alkyl-NR7—, in particular propyl, -ethyl-NR7— or -propyl-NR7—; —Y— represents-NR2—C1-6alkyl-CO—NR4—, -Het1-C1-6alkyl-CO—NR5— or -Het2-CO—NR6— and wherein the —C1-6alkyl-linker of —NR2—C1-6alkyl-CO—NR4— or -Het1-C1-6alkyl-CO—NR5— is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo and phenyl; R1 represents hydrogen, chloro, fluoro or bromo; R2 represents —C1-4alkyl-, in particular ethyl or methyl; R7 represents hydrogen; R8 represents hydrogen; R4, R5 and R6 represent hydrogen; Het1 is selected from piperazinyl or piperidinyl, in particular -piperazinyl; Het2 selected from pyrrolidinyl or piperidinyl, in particular pyrrolidinyl wherein said pyrrolidinyl is optionally substituted with hydroxy.